Clinical Trial Update: First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors [Phase 1]

View source ↗

Summary

Relay Therapeutics' first-in-human Phase 1 study of RLY-5836 in advanced breast cancer and other solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• RLY-5836

Snippet

Sponsor: Relay Therapeutics, Inc. | Conditions: PIK3CA Mutation, Solid Tumor, Adult | Phase 1 | Status: COMPLETED